Axa
YMAB

Axa’s Y-mAbs Therapeutics YMAB Stock Holding History

Axa’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-94,615
Closed -$4.68M – 1351
2020
Q4 		$4.68M Sell
94,615
-94,582
-50% -$4.38M 0.01% 706
2020
Q3 		$7.26M Sell
189,197
-1,828
-1% -$72.8K 0.03% 538
2020
Q2 		$8.25M Sell
191,025
-51,255
-21% -$1.94M 0.03% 480
2020
Q1 		$6.32M Buy
242,280
+13,769
+6% +$400K 0.03% 466
2019
Q4 		$7.14M Buy
228,511
+73,006
+47% +$2.16M 0.03% 527
2019
Q3 		$4.05M Sell
155,505
-137
-0.1% -$3.5K 0.02% 708
2019
Q2 		$3.56M Buy
+155,642
New +$3.57M 0.01% 739

Other funds holding YMAB

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Axa's YMAB Position: Q1 2021 in Review

Axa sold out of Y-mAbs Therapeutics (YMAB) in Q1 2021, closing a stake of 94,615 shares — an estimated $4.68M sold.

Axa first reported a position in YMAB in Q2 2019 and held it in 7 quarters. The position peaked at $8.25M in Q2 2020. 117 funds tracked by Wall St. Rank hold YMAB as of Q1 2021.

  • Axa reported no remaining Y-mAbs Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Axa sold 94,615 Y-mAbs Therapeutics shares in Q1 2021, an estimated $4.68M.
  • Axa first reported a position in Y-mAbs Therapeutics in Q2 2019 and held it in 7 quarters.
  • Axa's Y-mAbs Therapeutics position peaked at $8.25M in Q2 2020.
  • 117 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q1 2021.

Based on Axa's 13F filing for Q1 2021, filed 14 May 2021.